Targeting the mTOR Pathway in Hepatocellular Carcinoma: The Therapeutic Potential of Natural Products

Guo Chen1, Ya Zhang2, Yaqiao Zhou3

  • 1Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.

PubMed

Insights

Natural products can inhibit the mammalian target of rapamycin (mTOR) signaling pathway, offering a promising strategy to combat hepatocellular carcinoma (HCC). These compounds enhance combination therapies and overcome drug resistance in HCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) presents a significant therapeutic challenge due to low survival rates.
  • The mammalian target of rapamycin (mTOR) signaling pathway is frequently dysregulated in HCC, driving cancer progression.
  • mTOR pathway activation is implicated in cell cycle regulation, proliferation, apoptosis, and metabolic reprogramming in HCC.

Purpose of the Study:

  • To review the role of the mTOR signaling pathway in HCC.
  • To explore the potential of natural products in modulating the mTOR pathway for HCC therapy.
  • To highlight the use of natural products in combination therapies to improve HCC treatment outcomes.

Main Methods:

  • Literature review focusing on the mTOR signaling pathway in HCC.
  • Analysis of studies investigating natural products as modulators of mTOR.
  • Examination of evidence for natural products in combination therapies against HCC.

Main Results:

  • The mTOR pathway is a critical regulator of HCC cell proliferation, apoptosis, autophagy, cell cycle, and metabolism.
  • Several natural products, including 11-epi-sinulariolide acetate, matrine, and asparagus polysaccharide, inhibit mTOR signaling.
  • These natural products demonstrate potential in combination therapies to enhance efficacy and overcome chemoresistance in HCC.

Conclusions:

  • Targeting the mTOR signaling pathway is a viable strategy for HCC treatment.
  • Natural products show promise as mTOR inhibitors and as adjuncts in combination therapies for HCC.
  • Phytochemicals targeting the mTOR pathway offer potential for developing novel anti-HCC agents and overcoming drug resistance.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K